

blood

2008 112: 1784-1793
Prepublished online Jun 25, 2008;
doi:10.1182/blood-2008-02-142745

STAT3 is required for IL-21 induced secretion of IgE from human naive B cells

Danielle T. Avery, Cindy S. Ma, Vanessa L. Bryant, Brigitte Santner-Nanan, Ralph Nanan, Melanie Wong, David A. Fulcher, Matthew C. Cook and Stuart G. Tangye

Updated information and services can be found at:

<http://bloodjournal.hematologylibrary.org/cgi/content/full/112/5/1784>

Articles on similar topics may be found in the following *Blood* collections:

[Immunobiology](#) (3633 articles)

Information about reproducing this article in parts or in its entirety may be found online at:

http://bloodjournal.hematologylibrary.org/misc/rights.dtl#repub_requests

Information about ordering reprints may be found online at:

<http://bloodjournal.hematologylibrary.org/misc/rights.dtl#reprints>

Information about subscriptions and ASH membership may be found online at:

<http://bloodjournal.hematologylibrary.org/subscriptions/index.dtl>

Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published semimonthly by the American Society of Hematology, 1900 M St, NW, Suite 200, Washington DC 20036.

Copyright 2007 by The American Society of Hematology; all rights reserved.



STAT3 is required for IL-21–induced secretion of IgE from human naive B cells

Danielle T. Avery,¹ Cindy S. Ma,¹ Vanessa L. Bryant,¹ Brigitte Santner-Nanan,² Ralph Nanan,² Melanie Wong,³ David A. Fulcher,⁴ Matthew C. Cook,⁵ and Stuart G. Tangye¹

¹Immunology and Inflammation Group, Garvan Institute of Medical Research, Darlinghurst; ²Discipline of Paediatrics, Nepean Clinical School, University of Sydney, Penrith; ³Department of Immunology and Allergy, Children's Hospital, Westmead; ⁴Immunology Unit, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead; and ⁵Department of Immunology, Canberra Hospital, Woden, Australia

The production of immunoglobulin E (IgE) is tightly regulated. This is evidenced by the fact that it comprises less than 0.0001% of serum Ig, and aberrant production causes atopic conditions, including allergy, rhinitis, and anaphylaxis. Interleukin-4 (IL-4) is a well-characterized inducer of IgE by human and murine B cells, whereas interferon- γ can antagonize this effect. IL-21 has also been recognized for its ability to suppress IL-4–induced IgE

production by murine B cells. Here, we identified IL-21 as an inducer of IgE production by CD40L-stimulated human naive B cells. Furthermore, there was a striking synergy between IL-4 and IL-21 on inducing IgE secretion by CD40L-stimulated human B cells, such that the levels detected under these conditions exceeded those induced by IL-4 or IL-21 alone by more than 10-fold. IL-21 induced activation of STAT3 and analysis of B cells

from patients with loss-of-function *STAT3* mutations revealed that the ability of IL-21 to induce IgE secretion, and augment that driven by IL-4, was *STAT3*-dependent. These findings highlight a fundamental difference between the regulation of IgE production by human and murine B cells and have implications for the dysregulated production of IgE in conditions characterized by extremely high levels of serum IgE. (Blood. 2008;112:1784-1793)

Introduction

In normal individuals, the concentration of serum immunoglobulin E (IgE) is approximately 100 ng/mL, 10^4 to 10^5 times lower than IgG and IgA, making it the least abundant serum Ig.¹ However, aberrant production of IgE, often resulting from dysregulated Th2 or deficient Th1 responses, is associated with numerous diseases, including atopy, allergy, asthma, eczema/dermatitis, and parasitic infections.² Furthermore, extraordinarily high levels of IgE are present in patients with hyper-IgE syndrome (HIES), Ommen syndrome, Wiskott-Aldrich syndrome, Comel-Netherton syndrome, and immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome, diseases also associated with eczema, allergy, and atopy.^{2,3} Thus, to maintain IgE at normal (nonpathogenic) levels, its production must be strictly regulated. Identification of modulators of IgE production is therefore critical for understanding the pathogenesis of, and designing novel therapeutics for, conditions such as allergy and atopy.

It is well established that interleukin-4 (IL-4) induces IgE production by human and murine B cells.^{4,5} Human B cells also produce IgE when stimulated with IL-13.^{2,6,7} Several factors, such as interferon- γ (IFN- γ), IFN- α , transforming growth factor- β , IL-10, and prostaglandins, have been identified that antagonize IL-4-induced IgE production by human and murine B cells.^{2,4,5,8-10} Recent studies have also revealed that IL-21 inhibits IL-4–induced IgE secretion by murine B cells.¹¹⁻¹⁵ The increased levels of serum IgE in IL-21R– or IL-21–deficient mice^{11,13} most probably results from the ability of IL-21 to directly inhibit isotype switching to IgE by their B cells.¹² Despite these findings, the effects of IL-21 on

IgE secretion by human B cells remain incompletely characterized. On one hand, IL-21 inhibited IL-4–induced IgE secretion in cultures of total peripheral blood mononuclear cells (PBMCs)^{16,17} by inducing apoptosis of B cells committed to producing IgE and/or inducing IFN- γ production by non-B cells in the PBMCs.^{14,17} On the other hand, IL-21 had no effect on IgE secretion by human B cells stimulated with anti-CD40 monoclonal antibody (mAb),^{18,19} yet it did enhance IgE secretion induced by anti-CD40 mAb and IL-4.^{16-18,20}

Because of conflicting reports on the role of IL-21 in switching to IgE by human B cells, and potential differences in regulating IgE by human and murine B cells, we examined the effect of IL-21 on IgE secretion by human naive B cells. IL-21 induced IgE secretion by CD40L-stimulated naive B cells. Furthermore, addition of both IL-4 and IL-21 to CD40L-stimulated human B cells resulted in potent synergy, inducing 10- to 100-fold higher levels of IgE than those induced by IL-4 or IL-21 alone. One explanation for the interplay between IL-4 and IL-21 resulting in secretion of large amounts of IgE was the concomitant phosphorylation and activation of STAT3 and STAT6 in the majority of stimulated B cells. Indeed, the synergistic effect of IL-21 and IL-4 on IgE secretion was attenuated when B cells from patients with loss-of-function *STAT3* mutations were examined. These results suggest that both IL-4 and IL-21 positively regulate IgE production by human B cells. Aberrant production of, or signaling by, either of these cytokines may underlie excessive production of IgE in certain diseases. Thus, targeting IL-21 may be a means of treating these disorders.

Submitted February 27, 2008; accepted June 4, 2008. Prepublished online as *Blood* First Edition paper, June 25, 2008; DOI 10.1182/blood-2008-02-142745.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2008 by The American Society of Hematology

Methods

mAbs and reagents

The following mAbs were used: fluorescein isothiocyanate-anti-CD20, allophycocyanin-anti-CD10 (BD Biosciences, San Jose, CA); phycoerythrin-anti-CD23 (eBioscience, San Diego, CA); phycoerythrin-anti-CD27, anti-STAT1, anti-STAT3, Alexa488-anti-STAT5, Alexa647-anti-STAT6 (BD Biosciences Pharmingen, San Diego, CA); and neutralizing anti-IL-6 mAb (R&D Systems, Minneapolis, MN). Membranes of insect cells infected with baculovirus expressing recombinant human CD40L have been described.²¹ Human IL-4 and neutralizing anti-IL-4 mAb (MP4-25D2) were provided by Dr Rene de Waal Malefyt (DNAX Research, Palo Alto, CA). Human IL-21 was from PeproTech (Rocky Hill, NJ).

Lymphocyte purification and phenotyping

Cord blood (CB) and peripheral blood (PB) were collected from healthy donors and patients with HIES resulting from *STAT3* mutations.^{22,23} The clinical details, *STAT3* mutations, and serum IgE levels of HIES patients are described elsewhere.²⁴ B cells were isolated from PBMCs by Negative Isolation (DynaL Biotech, Oslo, Norway) and then sorted into transitional (CD20⁺CD10⁺CD27⁻), naive (CD20⁺CD10⁻CD27⁻), and memory (CD20⁺CD10⁻CD27⁺) populations.²⁵⁻²⁷ Expression of CD23 on naive and memory B cells from normal donors and HIES patients was determined using mAb to CD20, CD27, and CD23 and then gating on CD20⁺CD27⁻ and CD20⁺CD27⁺ B cells, respectively.^{25,26} CD4⁺ T cells were isolated using CD4-Beads (DynaL Biotech).²⁸ The purity for each population was more than 98%. All studies were approved by Sydney South West Area Health Service Human Research Ethics committee (X03-0317, X04-0122, and X06-0013), in accordance with the Declaration of Helsinki.

Lymphocyte cultures

B cells (0.5–50 × 10³/200 μL) were cultured with CD40L alone or with IL-4 (100 U/mL), IL-21 (5–100 ng/mL), or IL-4 plus IL-21, in the absence or presence of a neutralizing anti-IL-4 or IL-6 mAb (20 μg/mL). To examine the role of cell division in IgE secretion, CB B cells were labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE)^{21,29} and cultured with CD40L, CD40L/IL-4, CD40L/IL-21, or CD40L/IL-4/IL-21. After 5 days, cells were harvested, sorted into distinct division intervals, and recultured (~10–20 × 10³ cells/200 μL) for 2 days with CD40L (for initial cultures with CD40L or CD40L/IL-4) or CD40L plus IL-21 (for initial cultures with CD40L/IL-21 or CD40L/IL-4/IL-21). IL-4 was excluded from secondary cultures as it induced apoptosis of preactivated B cells (not shown). CD4⁺ T cells (30 × 10³ cells/well/200 μL) were cultured with anti-CD3 mAb (5 μg/mL; SpvT3) with or without in anti-CD28 mAb (750 ng/mL; BD Biosciences Pharmingen), IL-2 (20 U/mL; Pierce Endogen, Rockford, IL) or IL-21 (50 ng/mL).²⁸ IFN-γ and IL-10 secretion was measured by enzyme-linked immunosorbent assay.²⁴

Detection of secreted IgE

Microtiter plates were coated with anti-human IgE mAb (Southern Biotechnology, Birmingham, AL) and blocked with 2% fetal calf serum/phosphate-buffered saline (FCS/PBS). Culture supernatants and IgE myeloma standard (Calbiochem, San Diego, CA) were added to the wells and incubated for 2 hours at 37°C before adding biotin-conjugated anti-human IgE mAb (Southern Biotechnology). Bound Ab was detected with streptavidin-horseradish peroxidase (Jackson ImmunoResearch, West Grove, PA) and visualized with tetramethylbenzidine (Sigma-Aldrich, St Louis, MO).

Expression of phosphorylated STATs

B cells were unstimulated or stimulated with CD40L alone or with IL-4, IL-21, or IL-4/IL-21 for 16 hours, then harvested, fixed in 2% formaldehyde, permeabilized in 90% methanol, and labeled with antiphospho-STAT1, STAT3, STAT5, or STAT6 mAb.³⁰

Results

IL-21 induces CD40L-stimulated human cord blood B cells to secrete IgE

Previous studies found that IL-21 did not induce IgE secretion by anti-CD40 mAb-treated human B cells,^{18,19} yet it could increase IgE secretion by anti-CD40/IL-4-stimulated PBMCs.^{16-18,20} The findings from PBMCs are difficult to interpret because the net outcome of IL-21 stimulation could reflect a direct effect on B cells and/or an indirect effect on CD4⁺ T cells, NK cells, or NKT cells, which can all respond to IL-21³¹⁻³⁴ and modulate Ig production.^{2,35,36} For these reasons, we stimulated naive CB B cells with CD40L plus or minus IL-21 and examined IgE secretion. CB B cells were also cultured with CD40L/IL-4, a known inducer of IgE secretion.^{4,7,37}

Culture of CB B cells with CD40L/IL-4, but not CD40L alone, yielded low but detectable amounts of IgE (Figure 1A). CB B cells also produced IgE when cultured with CD40L/IL-21 (Figure 1A). Strikingly, IgE production by CB B cells stimulated with CD40L and IL-4 or IL-21 was augmented 10- to 20-fold in the presence of both cytokines (Figure 1A). Thus, IL-21-like IL-4 can induce human CB B cells to produce IgE, and these 2 cytokines synergize to induce very high levels of IgE.

The effects of IL-21 on IgE secretion are time-, dose-, and density-dependent

To investigate further the effects of IL-21 on IgE secretion, CB B cells were stimulated with CD40L alone or with IL-4 and/or IL-21 and IgE measured after different times. Low levels of IgE were produced after 4 to 6 days of in vitro culture with IL-4 or IL-21, whereas IL-4/IL-21 resulted in detectable IgE levels by 2 to 4 days (Figure 1B). Whereas the amount of IgE induced by CD40L/IL-4 or CD40L/IL-21 remained low for the entire culture period, the combination of IL-4 and IL-21 resulted in a large increase in IgE after 4 to 6 days (Figure 1B). Next, CB B cells were stimulated with CD40L and increasing doses of IL-21. IL-21 induced IgE secretion when used at 50 ng/mL (Figure 1C). When CB B cells were stimulated with CD40L, a fixed dose of IL-4 (100 U/mL), and increasing concentrations of IL-21, the synergistic effect of these 2 cytokines was clear. Under these conditions, CB B cells secreted IgE in response to doses of IL-21 that had minimal effect when used alone (ie, 5–25 ng/mL of IL-21; Figure 1C). Thus, although IL-4 or IL-21 could induce CD40L-stimulated B cells to secrete IgE, the addition of both IL-4 and IL-21 increased the sensitivity of CB B cells to the stimulatory effects of these cytokines, as evidenced by a requirement for a reduced concentration of IL-21 to induce IgE secretion.

It was recently reported that IL-4 and IL-21 maximally induced IgE production by CD40L-stimulated IgD⁺ tonsil B cells when cultured at densities of approximately 3 × 10³ cells/well, whereas higher cell densities inhibited IgE production. In contrast, the greatest effect of IL-4 alone occurred at approximately 10 × 10³ cells/well.²⁰ The effect of IL-21 alone on IgE secretion was not examined in this study.²⁰ To investigate whether IL-4 and IL-21 exhibited similar density-dependent effects in our system, increasing numbers (5 × 10² to 10⁴) of CB B cells were cultured with CD40L plus or minus IL-4, IL-21, and IL-4/IL-21. IgE production was detected in cultures seeded with 25 to 50 × 10³ B cells and stimulated with CD40L/IL-21 (Figure 1D). In contrast, IgE secretion was detected when as few as 500 B cells




Figure 1. IL-21 induces IgE secretion by human naive cord blood B cells and synergizes with IL-4 to induce high-level production of IgE. (A-D) CB B cells were cultured at (A-C) 10×10^3 cells/200 μ L per well; (D) 5×10^2 to 50×10^3 /well with (A,B) CD40L alone (■) or with IL-4 (100 U/mL; ▲), IL-21 (50 ng/mL; ▼), or both IL-4 and IL-21 (●). (C) CD40L and increasing concentrations of IL-21 (0–50 ng/mL) only (■) or together with 100 U/mL IL-4 (▲). Culture supernatants were collected after 10 to 14 days (A,C,D) or at the indicated times (B) and the amount of secreted IgE determined by IgE heavy chain-specific enzyme-linked immunosorbent assay. The results in panel A represent the mean plus or minus SEM of data from 8 independent experiments; those results in panels B, C, and D are representative of multiple experiments performed using B cells from different CB donors. (E,F) CB B cells were labeled with CFSE and then cultured with CD40L alone (■) or together with IL-4 (▲), IL-21 (▼), or IL-4 plus IL-21 (●). After 5 days, the cells were resorted into different division intervals based on dilution of CFSE (E; representing the division profile of cells stimulated with CD40L/IL-21), and equal numbers of cells then recultured for a further 2 days. After this time, secretion of (F) IgE was determined.

were cultured with CD40L/IL-4/IL-21 (Figure 1D). The greatest amounts of IgE were noted in cultures established with 5 to 10×10^3 CB B cells, and IgE secretion was dramatically reduced in cultures containing more than 20×10^3 B cells. Thus, consistent with Caven et al,²⁰ induction of high levels of IgE by CD40L/IL-4/IL-21-stimulated B cells is modulated by cell density.

Differentiation of human B cells to IgE-secreting cells is linked to cell division

Isotype switching is linked to cell division.^{21,29,38} It was therefore of interest to assess the role of division in switching to IgE by human B cells. CFSE-labeled CB B cells were cultured with CD40L plus or minus IL-4, IL-21, or IL-4/IL-21. After 5 days, cells were sorted from individual division intervals (Figure 1E), recultured for a further 2 days, and IgE secretion assessed. Dividing B cells isolated after primary culture with CD40L did not produce detectable levels of IgE, whereas initial culture with CD40L/IL-4 or CD40L/IL-21 resulted in the detection of trace amounts (IL-4, < 5 ng/mL; IL-21, 5–10 ng/mL) of IgE from cells that had undergone more than 2 divisions (Figure 1F). However, CB B cells initially cultured with CD40L/IL-4/IL-21 secreted substantially higher levels of IgE on a per-division basis. IgE secretion was detected once B cells had undergone 4 divisions before sorting, and the amount produced increased with each subsequent division (Figure 1F). The levels of IgE secreted by highly divided B cells exceeded that detected in bulk cultures of total CB B cells by 5- to 10-fold. These data demonstrate that differentiation of human naive B cells into IgE-secreting B cells is linked to cell division.

IL-21 induces IgE production by distinct B cell subsets

Although both CB (Figure 1) and PB B cells (not shown) produced IgE after stimulation with CD40L/IL-21, the composition of these

B-cell populations is distinct: CB is enriched for transitional B cells, whereas PB contains a substantial fraction of CD27⁺ (ie, memory) B cells^{25–27} (Figure 2A,B). Thus, the B-cell subset(s) that produce IgE was determined by sorting PB transitional, naive, and memory B cells (Figure 2A,B). Transitional and naive B cells secreted low levels of IgE after stimulation with CD40L/IL-4 or CD40L/IL-21 (Figure 2C), and the combination of CD40L/IL-4/IL-21 increased IgE secretion by 10- to 30-fold over that induced by either cytokine alone. Memory B cells also produced substantial amounts of IgE when stimulated with CD40L/IL-4/IL-21 (Figure 2C). Thus, all subsets of mature B cells can produce increased levels of IgE after stimulation with CD40L, IL-4, and IL-21.

IL-21-induced IgE production is independent of endogenous IL-4 but partially dependent on IL-6

The finding that IL-21 induced IgE production by human B cells was surprising because IL-21 inhibits IgE secretion by murine B cells.^{11–15} It was therefore important to determine whether IL-21 had a direct effect on IgE secretion by human B cells. Although T cells are a main source of IL-4, it can also be produced by B cells.³⁹ Thus, one mechanism whereby IL-21 could indirectly induce IgE secretion would be by promoting IL-4 production, which would then act in an autocrine manner. To examine this possibility, CB B cells were cultured in the presence of a neutralizing IL-4 mAb. Whereas IgE secretion by CD40L-stimulated CB B cells induced by exogenous IL-4 was abrogated by anti-IL-4 mAb, IL-21-induced IgE was unaffected (Table 1, experiments 1, 2). Furthermore, the synergistic effect of IL-4 and IL-21 on IgE production by CD40L-stimulated CB B cells was reduced to the effect of IL-21 alone by anti-IL-4 mAb (Table 1, experiments 1, 2). The combined effect of IL-4 and IL-21 on IgE secretion was also unrelated to alterations in expression of their receptors because




Figure 2. IL-21 induces IgE secretion by human transitional, naive, and memory B cells. Human CB (A) and PB (B) MNCs were labeled with mAb specific for CD20, CD10, and CD27. The frequencies of transitional ($CD10^+CD27^-$), naive ($CD10^+CD27^-$), and memory ($CD10^+CD27^+$) cells were determined. Values represent the mean percentages of B-cell subsets in 12 CB and 8 PB samples. (C) Transitional, naive, and memory B cells were sort-purified and then cultured ($\sim 20 \times 10^3$ cells/200 μ L per well) with CD40L alone (□) or in combination with IL-4 (100 U/mL; ▨), IL-21 (50 ng/mL; ▩), or IL-4 plus IL-21 (■). After 12 to 14 days, supernatants were harvested and the amount of secreted IgE determined. The results are the means plus or minus SEM of data from 4 independent experiments using B-cell subsets isolated from 4 different blood donors.

neither IL-4 nor IL-21 enhanced the level of expression of the IL-21R or IL-4R, respectively, induced by CD40L on stimulated B cells (Figure S1, available on the *Blood* website; see the Supplemental Materials link at the top of the online article).

Because endogenous IL-6 can enhance IgE production induced by IL-4,⁴⁰ we investigated whether IL-6 also contributed to IgE production induced by IL-21 or IL-4/IL-21. Culturing CB B cells in the presence of neutralizing anti-IL-6 mAb did not affect IgE induced by CD40L/IL-21 (Table 1, experiments 3, 4). However, blocking endogenous IL-6 reduced CD40L/IL-4/IL-21-induced IgE secretion by approximately 50% (Table 1, experiments 3, 4).

Table 1. The ability of IL-21 to induce IgE secretion by CD40L-activated human B cells is independent of endogenous IL-4 but partially dependent on endogenous IL-6

Culture	IgE secretion (ng/mL)			
	No mAb	Control mAb	Anti-IL-4 mAb	Anti-IL-6 mAb
Experiment 1				
CD40L	<0.1	ND	ND	—
CD40L IL-4	7.6 \pm 0.32	ND	<0.1	—
CD40L IL-21	3.9 \pm 0.9	3.02 \pm 0.24	4.28 \pm 0.9	—
CD40L IL-4/IL-21	41.8 \pm 2.5	34.8 \pm 4.7	4.1 \pm 0.47	—
Experiment 2				
CD40L	<0.1	ND	ND	—
CD40L IL-4	1.90 \pm 0.3	ND	<0.1	—
CD40L IL-21	4.9 \pm 0.9	3.7 \pm 0.46	4.2 \pm 1.1	—
CD40L IL-4/IL-21	73.1 \pm 13.0	84.0 \pm 3.8	7.6 \pm 2.3	—
Experiment 3				
CD40L	<0.1	ND	—	<0.1
CD40L IL-4	<0.1	<0.1	—	<0.1
CD40L IL-21	<0.1	<0.1	—	<0.1
CD40L IL-4/IL-21	48.6 \pm 10	40.0 \pm 8.0	—	24.0 \pm 3.7
Experiment 4				
CD40L	<0.1	ND	—	<0.1
CD40L IL-4	<0.1	ND	—	<0.1
CD40L IL-21	6.4 \pm 2.2	ND	—	4.4 \pm 1.8
CD40L IL-4/IL-21	170 \pm 2.0	ND	—	80.6 \pm 18.2

B cells purified from different CB samples were cultured (~ 10 – 20×10^3 cells per 200 μ L per well) with CD40L alone or together with IL-4, IL-21, or both IL-4 and IL-21 in the absence or presence of a control mAb, neutralizing anti-IL-4 mAb (experiments 1, 2) or neutralizing anti-IL-6 mAb (experiments 3, 4). After 8 to 10 days, supernatants were harvested and the amount of secreted IgE determined by ELISA. These results represent the means plus or minus the SEM of replicate cultures.

ND indicates not done; and —, not applicable.

These results established that the ability of IL-21 to induce IgE secretion by CB B cells is independent of endogenous production of both IL-4 and IL-6, whereas the combined effect of IL-4 plus IL-21 is partially dependent on the action of autocrine IL-6.

Complementary phosphorylation of STAT proteins by IL-21 and IL-4 in naive B cells

Cytokine signaling induces phosphorylation of JAKs that associate with cytokine receptors and phosphorylate tyrosines in their cytoplasmic domains, which act as docking sites to recruit various STATs that undergo JAK-mediated tyrosine phosphorylation, dimerization, and activation.^{2,41} Although receptors for IL-4 and IL-21 share γ_c , engagement of the IL-4R and IL-21R complexes activates distinct signaling pathways. Thus, IL-4 activates STAT6,^{41,42} whereas IL-21 can activate STAT1, STAT3, and STAT5.^{12,43–47} We therefore explored the possibility that the synergistic effect of IL-4 and IL-21 on IgE production was achieved by concomitant activation of distinct STAT proteins in CD40L-stimulated B cells.

The phosphorylation status of STAT1, 3, 5, and 6 in CB B cells was assessed by flow cytometry using phospho-STAT mAbs. Stimulation of CB B cells with CD40L alone for 16 hours failed to induce phosphorylation of any of the STATs examined (Figure 3A,B). However, inclusion of IL-4 with CD40L resulted in phosphorylation of STAT6 in more than 50% of cells (Figure 3A,B). On the other hand, IL-21 induced phosphorylation of only STAT3 in activated CB B cells (Figure 3A). Similar to the effect of IL-4 on phospho-STAT6, more than 50% of IL-21-stimulated B cells expressed phospho-STAT3 (Figure 3B). The combination of IL-4 and IL-21 resulted in expression of both phospho-STAT3 and phospho-STAT6 by more than 40% of CD40L-stimulated CB B cells, and a greater frequency of cells expressing phospho-STAT6 (58% vs 71%; Figure 3A bottom panel; 3B). A recent study found that IL-21 rapidly and transiently activated STAT5 in human B cells that had been preactivated with CD40L for 36 hours.⁴⁷ Thus, we examined the kinetics of STAT phosphorylation in CD40L-stimulated B cells. IL-21 induced phosphorylation of STAT3 in CD40L-stimulated B cells within approximately 30 minutes of stimulation, and the levels of expression increased over the 18-hour stimulation period (Figure S2). In contrast, IL-21 had negligible effect on expression of phospho-STAT1 or STAT5 in the B cells at any of the times examined (Figure S2). Thus, IL-4 and IL-21 may achieve their synergistic effect by simultaneously activating target




Figure 3. Induction of phosphorylation of STAT proteins in stimulated CB B cells. (A) CB B cells were cultured in the absence or presence of CD40L with or without IL-4, IL-21, or both cytokines. After 16 hours, the cells were harvested, fixed, and permeabilized, and expression of phospho-STAT1, 3, 5, and 6 determined by immunofluorescence and flow cytometry. Solid histograms represent expression of phosphorylated STAT1, 3, 5, or 6 in the presence of the indicated stimulus; the dashed outline histograms represents expression of phosphorylated STATs in cells cultured in the absence of any exogenous stimulus. (B) Coexpression of STAT3 and STAT6 was determined for CB B cells stimulated with CD40L alone or together with IL-4, IL-21, or IL-4 and IL-21. The values represent the percentage of cells in each quadrant of the contour plot.

genes downstream of STAT3 and STAT6 in the majority of stimulated B cells.

STAT3 is required for IL-21-mediated induction of IgE secretion by human B cells

Heterozygous mutations in *STAT3* have recently been identified in individuals with HIES.^{22,23} Although serum IgE levels are increased in HIES patients with *STAT3* mutations, B cells from these patients represent a model system to determine whether the ability of IL-21 to induce IgE secretion by CD40L-stimulated B cells was STAT3-dependent. We identified 5 HIES patients with heterozygous mutations in either the DNA-binding or SH2-domains of *STAT3*.²⁴ Total B cells were isolated from HIES patients and normal controls. As expected, B cells from normal donors produced low amounts of IgE in response to CD40L and either IL-4 or IL-21, and 10- to 20-fold higher levels in the presence of both cytokines (Figure 4A). Whereas the ability of B cells from HIES patients to produce IgE in response to CD40L/IL-4 was intact, they completely failed to produce IgE after stimulation with CD40L/

IL-21 (Figure 4A). Furthermore, the synergistic effect of IL-4 plus IL-21 on IgE secretion by CD40L-stimulated B cells was significantly reduced by STAT3 mutations, as revealed by 3- to 10-fold less IgE secreted by HIES B cells stimulated with CD40L/IL-4/IL-21 relative to normal B cells (Figure 4A). Thus, functional STAT3 is required for IL-21 to induce high quantities of IgE induced by costimulation of human B cells with CD40L and IL-4.

Whereas the magnitude of the IgE response to CD40L/IL-4/IL-21 by HIES B cells was less than control B cells, detectable amounts of IgE were still secreted by HIES B cells that exceeded that induced by CD40L/IL-4. This suggested some residual STAT3 function in HIES B cells. Because the active form of STAT proteins consists of homodimers,⁴¹ heterozygous mutations would be expected to result in approximately 25% of STAT3 dimers comprising wild-type (STAT3_{WT}:STAT3_{WT}) protein, 50% comprising one WT and one mutant molecule (STAT3_{WT}:STAT3_{MUT}), and 25% being STAT3_{MUT}:STAT3_{MUT}. Thus, we hypothesized that the 25% STAT3_{WT}:STAT3_{WT} dimer activated in response to IL-21 would be sufficient to induce low levels of IgE when used with IL-4. To




Figure 4. IL-21-induced IgE secretion by human B cells is STAT3-dependent. (A) PB B cells from 5 healthy donors (●) and 5 HIES patients with heterozygous STAT3 mutations (○) were cultured ($\sim 20 \times 10^3$ cells/200 μ L per well) in quadruplicate with CD40L, CD40L/IL-4 (100 U/mL), CD40L/IL-21 (50 ng/mL), or CD40L/IL-4/IL-21 for 10 to 12 days. Each point represents IgE secretion by an individual normal donor or HIES patient; the gray column represents the mean. *** $P = .001$ (unpaired Student t test). (B,C) B cells from 2 donors (◇, ○) and 2 HIES patients (▲, ■) were cultured with CD40L and increasing concentrations of IL-21 (0–100 ng/mL) in the absence (B) or presence (C) of IL-4 (100 U/mL). IgE secretion was determined after 12 days. Note the different scales of the y-axes in panels B and C.

examine this in more detail, we cultured HIES B cells with CD40L and increasing doses of IL-21 in the absence or presence of 100 U/mL of IL-4. PB B cells from normal donors secreted low levels of IgE after stimulation with CD40L and more than 25 ng/mL of IL-21 (Figure 4B). Whereas less than 10 ng/mL of IL-21 alone did not result in IgE secretion (Figure 4B), these low doses increased IL-4-induced IgE production by 10-fold (Figure 4C). In contrast, B cells from HIES patients failed to produce IgE at any of the doses of IL-21 tested alone (Figure 4B), and the IL-4-induced production of IgE was barely affected by IL-21 when added at 1 to 25 ng/mL (Figure 4C). Despite this, higher doses of IL-21 were capable of augmenting IgE secretion by HIES B cells induced by IL-4 (Figure 4C). Thus, B cells with STAT3 mutations fail to respond to limiting doses of IL-21, most probably because of insufficient STAT3_{WT}:STAT3_{WT} dimers. However, this impairment is partially corrected by increasing the dose of IL-21 and presumably the content of STAT3_{WT}:STAT3_{WT} dimers.

Elevated expression of B-cell CD23 and impaired production of IFN- γ and IL-10 by CD4⁺ T cells suggests dysregulated IL-4 signaling in HIES

The finding that STAT3_{MUT} B cells cannot produce high levels of IgE in vitro in response to IL-21 does not explain the extreme levels of serum IgE in HIES patients. Because IL-4 is a major regulator of IgE production,² we sought to determine whether there may be heightened IL-4 signaling in HIES B cells. Because IL-4 strongly up-regulates CD23 on human B cells,^{6,48,49} we examined its expression. In normal donors, CD23 is expressed by naive but not memory B cells (Figure 5A,B).^{25,26} Strikingly, the level of CD23 on naive HIES B cells exceeded that on normal naive cells by 5-fold (Figure 5A). Furthermore, memory B cells from HIES patients expressed CD23 at a level that exceeded normal memory cells by approximately 10-fold (Figure 5B), such that its expression pattern resembled normal naive B cells.

IFN- γ and IL-10 antagonize the effects of IL-4 on IgE secretion^{9,10,49} and CD23 expression.⁴⁹ Furthermore, PBMCs from HIES patients exhibit reduced expression and production of IFN- γ mRNA⁵⁰ and protein.^{51–54} Thus, we speculated that production of IFN- γ and IL-10 by HIES CD4⁺ T cells may be impaired. CD4⁺ T cells from normal donors failed to produce IFN- γ in response to stimulation with anti-CD3 alone or in combination with anti-CD28 (Figure 5C). However, adding IL-2 to these cultures induced IFN- γ production, with higher amounts being produced by cells stimulated with anti-CD3/CD28 plus IL-2 (Figure 5C). Whereas HIES

CD4⁺ T cells also secreted IFN- γ after stimulation with anti-CD3/IL-2, the levels were approximately 5-fold lower than those of normal CD4⁺ T cells. Furthermore, anti-CD28 mAbs failed to augment anti-CD3/IL-2–induced IFN- γ production, thereby revealing a 10-fold difference in IFN- γ secretion by anti-CD3/CD28/IL-2–stimulated normal and HIES CD4⁺ T cells (Figure 5C). HIES CD4⁺ T cells also failed to produce IL-10 in response to anti-CD3/CD28 stimulation (Figure 5D). Furthermore, whereas IL-10 production by normal CD4⁺ T cells could be increased by IL-2 or IL-21, these cytokines had no effect on HIES CD4⁺ T cells (Figure 5D). The inability of HIES CD4⁺ T cells to respond to IL-21 is consistent with IL-21 activating STAT3 in T cells.⁴² Thus, reduced production of IFN- γ and IL-10 by CD4⁺ T cells in vivo may contribute to sustained IL-4 signaling in HIES B cells, which may underlie increased levels of serum IgE in this disease.

Discussion

Secretion of IgE is a strictly regulated process, as evidenced by the fact that IgE comprises less than 0.0001% of all serum Ig.¹ Dysregulated IgE production can cause immunopathologies, such as allergy and atopy, and levels of IgE are extremely high in some human genetic diseases, such as HIES, Wiskott-Aldrich syndrome, Omenn's syndrome, and immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome.^{2,3} It is therefore important to identify regulators of IgE production. Studies in mice^{11–14} led to the conclusion that IL-21 has an important role in suppressing IgE production in vivo and may therefore have application in treating numerous IgE-mediated pathologies. Indeed, administration of IL-21 in vivo efficiently attenuated symptoms in animal models of allergic rhinitis and anaphylaxis.^{15,55}

In striking contrast to its effect on murine B cells, we identified IL-21 as an inducer of IgE production by CD40L-stimulated human B cells. Furthermore, IL-4 and IL-21 synergized to increase IgE secretion by all B-cell subsets by more than 10-fold. Importantly, the synergy between IL-4 and IL-21 was evident at concentrations that failed to induce IgE secretion when used alone. Because B cells are probably exposed to limiting cytokine concentrations in vivo, such synergy at low doses of IL-4 and IL-21 implies that these cytokines may cooperate to regulate IgE production in vivo. In complementary studies, we have also found that combining IL-4 and IL-21 has diverse effects on isotype




Figure 5. Aberrant expression of CD23 on B cells and impaired production of IFN- γ and IL-10 by CD4⁺ T cells from STAT3 mutant patients suggests dysregulated IL-4 signaling in HIES. Expression of CD23 on ex vivo isolated naive (A; CD20⁺CD27⁻) and memory (B; CD20⁺CD27⁺) B cells from healthy donors (open black histogram) and HIES patients (solid gray histogram) was determined by flow cytometry. Panels A and B are representative histograms; the values are the mean fluorescence intensity plus or minus SEM of CD23 on naive and memory B cells from 5 controls and 4 HIES patients. (C,D) CD4⁺ T cells isolated from a normal donor (■) and HIES patient (□) were cultured for 5 days with immobilized anti-CD3 mAb in the absence or presence of IL-2, soluble anti-CD28 mAb, or IL-21. Secretion of (C) IFN- γ and (D) IL-10 was determined after 5 days of culture. The values represent the means plus or minus SD of triplicate cultures.


switching and Ig secretion by human naive B cells.⁵⁶ IL-4 increased the frequency of IgG⁺ B cells induced in cultures of B cells stimulated with CD40L/IL-21; this predominantly resulted from IL-4 inducing the appearance of IgG₁⁺ B cells. Despite this, secretion of IgG subclasses induced by IL-21 is not dramatically altered by IL-4. Furthermore, IL-4 inhibits IL-21-induced isotype switching to, and secretion of, IgA.⁵⁶ Thus, the ability of IL-4 and IL-21 to synergize to induce secretion of large amounts of IgE is unique to this Ig isotype. Our results contrast previous studies, which found that IL-21 did not induce IgE secretion by human B cells.¹⁶⁻²⁰ This probably reflects our use of multimeric CD40L as a B-cell stimulus, whereas other groups used soluble anti-CD40 mAb. Indeed, anti-CD40 mAb induces significantly less proliferation⁷ and IgE secretion by human B cells than CD40L (Figure S3). The fact that CD40L (Figure S3),^{57,58} but not anti-CD40,^{8,16,17,59,60} induced IgE germ line transcripts (GLT) in human B cells provides additional evidence for differences in the quality of signals delivered by CD40L and anti-CD40 mAb in the context of inducing IgE secretion.

Our results identified some of the requirements for IL-21-mediated induction of IgE production by human B cells, and the means by which signaling through the IL-21R and IL-4R interact to yield substantially greater levels of IgE. First, IgE production by B cells activated with CD40L, IL-4, and IL-21 was underpinned by cell division. This highlights the importance of signals that sustain or perpetuate cell division, such as continued presence of Ag or availability of T-cell help, in immune responses. Second, IL-21-induced IgE production was abolished in B cells with STAT3 mutations, thus revealing an obligatory role for STAT3 in this process. This is consistent with our finding that IL-21 induced

activation of only STAT3 in human B cells. Thus, whereas STAT1 and STAT5 may mediate some effects of IL-21,^{12,43-47} loss of STAT3 function could not be compensated by other STATs indicating that STAT3 is necessary and sufficient for IL-21-induced IgE production. Third, the combination of IL-4 and IL-21 resulted in a large proportion of B cells expressing phosphorylated STAT6 and STAT3. Thus, stimulation with CD40L, IL-4, and IL-21 would activate a suite of STAT3 and STAT6 target genes in the same population of human B cells, thereby potentially contributing to the high levels of IgE observed. Fourth, IgE production induced by CD40L/IL-4/IL-21 was partially reduced by neutralizing endogenous IL-6. This is consistent with the finding that IL-4 induces production of IL-6 by CD40L-stimulated naive B cells, and this can be increased by IL-21.⁵⁶ Because IL-6 activates STAT3,⁴² the involvement of IL-6 in this process would also contribute to impaired IgE secretion by STAT3 mutant B cells in response to these stimulatory conditions.

Activation of different STATs by IL-4 and IL-21 implies that these cytokines induce IgE production by distinct mechanisms. Indeed, IL-4, but not IL-21, induced IgE GLTs in human B cells (Figure S3).^{8,16,17,59} Thus, IL-4 probably induces IgE secretion by facilitating isotype switching through a process involving expression of GLTs,^{8,59} whereas IL-21 may achieve this by promoting expansion of naive B cells that either constitutively express IgE GLTs or acquire expression after CD40L stimulation.^{57,58} The use of different STAT signaling pathways by IL-4 and IL-21 may also explain why additional functions of these cytokines are not shared. For instance, IL-4 increases CD23 expression on human B cells,^{67,48} yet IL-21 had no effect (not shown). Thus, it will be important to

Figure 6. Model of cytokine-mediated regulation of IgE production: role of STAT3. (A) Under normal conditions, CD4⁺ T (and NK T) cells produce IL-4, IL-21, IL-10, and IFN- γ (among other cytokines) in response to stimulation through the TcR. Production of IFN- γ ³²⁻³⁴ and IL-10 (Figure 5) can be enhanced by IL-21. IL-4, and IL-21 alone can induce IgE secretion by naive B cells; however, they act synergistically in a STAT3-dependent manner to promote secretion of high levels of IgE. Induction of IgE by IL-4 is negatively regulated by IL-10 and IFN- γ ; the net result of the interplay between IL-4, IL-21, IL-10, and IFN- γ is production of a low basal level of IgE. (B) In HIES because of mutations in STAT3, the ability of (for example) IL-21 to heighten IL-10 and IFN- γ production by activated CD4⁺ T (and NKT) cells is abrogated; consequently, the suppressive effects of these cytokines on IgE production are attenuated. This is further compounded by the inability of HIES B cells to respond to the regulatory effects of IL-10, which acts through STAT3. Thus, despite the B cells being unable to respond to the regulatory effects of IL-10, their responses to the stimulatory effects of IL-4 are dysregulated, resulting in excessive production of IgE, a hallmark of HIES.



identify IL-21-induced genes that mediate the effects of this cytokine.

Because IL-21 can activate STAT3^{12,44,45} and suppress IgE secretion by murine B cells,¹¹⁻¹⁵ it was postulated that the lack of a direct effect of IL-21 on inhibiting IgE secretion by human B cells because of loss-of-function *STAT3* mutations would contribute to the elevated levels of IgE in HIES.²³ However, the finding that IL-21 induced IgE secretion in a STAT3-dependent pathway implies that this scenario does not explain the abnormally high levels of serum IgE in HIES. Despite this, we can propose several mechanisms that may contribute to dysregulated IgE production in HIES. First, IL-21 can activate STAT3 in human NK and T cells and induce them to produce IFN- γ .^{17,31-34} Consequently, adding IL-21 to cultures of IL-4-stimulated human PBMCs indirectly inhibits IgE production in an IFN- γ -dependent manner.¹⁷ Thus, impaired production of IFN- γ by T and NK cells with *STAT3* mutations may favor elevated production of IgE in HIES (Figure 6). A deficiency in IFN- γ -mediated regulation of B-cell activation in HIES is supported by several observations: 1) heightened expression of CD23 on HIES patients B cells (Figure 5A,B), and increased serum soluble CD23 in HIES,⁵² inasmuch that IFN- γ can inhibit IL-4-induced up-regulation of CD23 expression on B cells⁴⁹; 2) reduced IFN- γ production by HIES PBMCs^{50,51,53,54} and CD4⁺ T cells (Figure 5D)⁶¹; 3) IFN- γ -mediated suppression of unusually high levels of IgE spontaneously produced by HIES PBMCs in vitro^{52,62}; and 4) administration of IFN- γ reduced spontaneous IgE secretion by HIES patients B cells in vitro, and serum IgE levels.⁶² Our hypothesis that reduced IFN- γ production by CD4⁺ T cells contributes to aberrant IgE production in HIES is supported by the findings that patients with mutations in *IL-12* or *IFN- γ R* have significantly elevated serum IgE levels and increased incidence of clinical atopic disease compared with controls.⁶³ Second, and similar to IFN- γ , it is possible that the regulatory effects of IL-10, which activates STAT3⁴² and inhibits IL-4-induced IgE production,^{9,10} are compromised by *STAT3* mutations. Indeed, *STAT3* mutations abolished production of IL-10 by CD4⁺ T cells.²⁴ This is

consistent with STAT3 regulating IL-10 production by murine T cells.⁶⁴ Notably, the ability of IL-21 to enhance IL-10 production was abrogated in HIES CD4⁺ T cells. Thus, it is probable that combined deficiencies in production of key cytokines that negatively regulate IL-4-induced IgE production by human B cells^{4,9,10} may contribute to dysregulation of IgE production in HIES. This would be further compounded by the inability of HIES B cells to respond to the regulatory effects of IL-10 because of *STAT3* mutations. A third explanation for aberrant IgE production comes from the recent findings that *STAT3* mutations prevent the generation of Th17 cells in HIES patients.^{24,61} It is possible that products of Th17 cells (IL-17, IL-22) suppress IgE secretion. However, this is unlikely because mature human B cells do not express receptors for these cytokines,^{30,65} and neither IL-17 nor IL-22 affected IgE secretion by human B cells (not shown).⁶⁵ Because human Th17 cells remain incompletely characterized, it remains possible that another Th17 molecule acts to suppress IL-4-induced IgE production. Lastly, the function of negative regulators of IgE production may be impaired in HIES. For instance, *bcl-6* suppresses IL-4-induced IgE secretion by antagonizing STAT6.^{2,66} Interestingly, *bcl-6* also represses IRF-4, which induces CD23 expression on activated B cells.⁶⁷ It is therefore possible that increased serum IgE levels and CD23 expression in HIES result from a reduction in expression and/or function of *bcl-6* in HIES B cells. These scenarios reinforce the likelihood that extreme levels of IgE in conditions such as HIES are a manifestation of excessive IL-4/STAT6-mediated B-cell activation; and although IL-21 can induce IgE secretion by human B cells, it does not directly contribute to dysregulated IgE production in HIES. Further investigation into the consequences of *STAT3* mutations on the behavior of CD4⁺ T cells, NK cells, and B cells with respect to cytokine production, effector function, and expression of transcriptional regulators of B-cell behavior will elucidate the mechanism(s) responsible for dysregulated IgE production in vivo in HIES. In the meantime, lymphocytes from HIES patients have provided a powerful system whereby we could demonstrate that (1) their B cells do not

intrinsically produce aberrantly high levels of IgE, revealing the defect is B-cell extrinsic, (2) STAT3 is required for IL-21-mediated IgE production by human B cells, and (3) reduced production of cytokines involved in negatively regulating IgE production is a possible mechanism for dysregulated IgE production in HIES. Finally, our results reveal significant differences between the regulation of IgE secretion by human and murine B cells, and caution against using IL-21 therapeutically for suppressing IgE-mediated human diseases. Indeed, administration of IL-21 to patients could exacerbate their condition. Alternatively, neutralizing IL-21 together with IL-4 may be a means of treating patients with IgE-mediated conditions.

Acknowledgments

The authors thank Royal Prince Alfred Hospital Birth Center for providing cord blood, Jerome Darakdjian for cell sorting, Rene de Waal Malefyt and Karen Fenimore-Pirog for reagents, and Dr Rob Brink and Prof Tony Basten for helpful discussion and critical review of this manuscript.

References

- Waldmann TA, Iio A, Ogawa M, McIntyre OR, Strober W. The metabolism of IgE. Studies in normal individuals and in a patient with IgE myeloma. *J Immunol*. 1976;117:1139-1144.
- Geha RS, Jabara HH, Brodeur SR. The regulation of immunoglobulin E class-switch recombination. *Nat Rev Immunol*. 2003;3:721-732.
- Grimbacher B, Belohradsky BH, Holland SM. Immunoglobulin E in primary immunodeficiency diseases. *Allergy*. 2002;57:995-1007.
- Pene J, Rousset F, Briere F, et al. IgE production by normal human lymphocytes is induced by IL-4 and suppressed by IFN gamma and alpha and prostaglandin E2. *Proc Natl Acad Sci U S A*. 1988;85:6880-6884.
- Snapper CM, Paul WE. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. *Science*. 1987;236:944-947.
- Punnonen J, Aversa G, Cocks BG, et al. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. *Proc Natl Acad Sci U S A*. 1993;90:3730-3734.
- Cocks BG, de Waal Malefyt R, Galizzi JP, de Vries JE, Aversa G. IL-13 induces proliferation and differentiation of human B cells activated by the CD40 ligand. *Int Immunol*. 1993;5:657-663.
- Gauchat JF, Aversa G, Gascan H, de Vries JE. Modulation of IL-4 induced germline epsilon RNA synthesis in human B cells by tumor necrosis factor-alpha, anti-CD40 monoclonal antibodies or transforming growth factor-beta correlates with levels of IgE production. *Int Immunol*. 1992;4:397-406.
- Punnonen J, de Waal Malefyt R, van Vlasselaer P, Gauchat JF, de Vries JE. IL-10 and viral IL-10 prevent IL-4-induced IgE synthesis by inhibiting the accessory cell function of monocytes. *J Immunol*. 1993;151:1280-1289.
- Jeannin P, Lecoanet S, Delneste Y, Gauchat JF, Bonnefoy JY. IgE versus IgG4 production can be differentially regulated by IL-10. *J Immunol*. 1998;160:3555-3561.
- Ozaki K, Spolski R, Feng CG, et al. A critical role for IL-21 in regulating immunoglobulin production. *Science*. 2002;298:1630-1634.
- Suto A, Nakajima H, Hirose K, et al. Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line C(epsilon) transcription of IL-4-stimulated B cells. *Blood*. 2002;100:4565-4573.
- Shang XZ, Ma KY, Radewonuk J, et al. IgE isotype switch and IgE production are enhanced in IL-21-deficient but not IFN-gamma-deficient mice in a Th2-biased response. *Cell Immunol*. 2006;241:66-74.
- Harada M, Magara-Koyanagi K, Watarai H, et al. IL-21-induced Bepsilon cell apoptosis mediated by natural killer T cells suppresses IgE responses. *J Exp Med*. 2006;203:2929-2937.
- Hiromura Y, Kishida T, Nakano H, et al. IL-21 administration into the nostril alleviates murine allergic rhinitis. *J Immunol*. 2007;179:7157-7165.
- Wood N, Bourque K, Donaldson DD, et al. IL-21 effects on human IgE production in response to IL-4 or IL-13. *Cell Immunol*. 2004;231:133-145.
- Pene J, Guglielmi L, Gauchat JF, et al. IFN-gamma-mediated inhibition of human IgE synthesis by IL-21 is associated with a polymorphism in the IL-21R gene. *J Immunol*. 2006;177:5006-5013.
- Pene J, Gauchat JF, Lecart S, et al. Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. *J Immunol*. 2004;172:5154-5157.
- Ettinger R, Sims GP, Fairhurst AM, et al. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. *J Immunol*. 2005;175:7867-7879.
- Caven TH, Shelburne A, Sato J, et al. IL-21 dependent IgE production in human and mouse in vitro culture systems is cell density and cell division dependent and is augmented by IL-10. *Cell Immunol*. 2005;238:123-134.
- Tangye SG, Ferguson A, Avery DT, Ma CS, Hodgkin PD. Isotype switching by human B cells is division-associated and regulated by cytokines. *J Immunol*. 2002;169:4298-4306.
- Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. *Nature*. 2007;448:1058-1062.
- Holland SM, Deleo FR, Elloumi HZ, et al. STAT3 mutations in hyper-IgE syndrome. *N Engl J Med*. 2007;357:1655-1658.
- Ma CS, Chew GYJ, Simpson N, et al. Hyper IgE syndrome due to mutations in STAT3 represents a deficiency of Th17 cells. *J Exp Med*. 2008;205:1551-1557.
- Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. *J Exp Med*. 1998;188:1679-1689.
- Tangye SG, Liu YJ, Aversa G, Phillips JH, de Vries JE. Identification of functional human splenic memory B cells by expression of CD148 and CD27. *J Exp Med*. 1998;188:1691-1703.
- Cuss AK, Avery DT, Cannons JL, et al. Expansion of functionally immature transitional B cells is associated with human-immunodeficient states characterized by impaired humoral immunity. *J Immunol*. 2006;176:1506-1516.
- Ma CS, Hare NJ, Nichols KE, et al. Impaired humoral immunity in X-linked lymphoproliferative disease is associated with defective IL-10 production by CD4+ T cells. *J Clin Invest*. 2005;115:1049-1059.
- Hodgkin PD, Lee JH, Lyons AB. B cell differentiation and isotype switching is related to division cycle number. *J Exp Med*. 1996;184:277-281.
- Good KL, Bryant VL, Tangye SG. Kinetics of human B cell behavior and amplification of proliferative responses after stimulation with IL-21. *J Immunol*. 2006;177:5236-5247.
- Brady J, Hayakawa Y, Smyth MJ, Nutt SL. IL-21 induces the functional maturation of murine NK cells. *J Immunol*. 2004;172:2048-2058.
- Coquet JM, Kyriakoudis K, Pellicci DG, et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. *J Immunol*. 2007;178:2827-2834.
- Strengell M, Matikainen S, Siren J, et al. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. *J Immunol*. 2003;170:5464-5469.
- Strengell M, Sareneva T, Foster D, Julkunen I, Matikainen S. IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. *J Immunol*. 2002;169:3600-3605.
- Gray JD, Horwitz DA. Activated human NK cells can stimulate resting B cells to secrete immunoglobulin. *J Immunol*. 1995;154:5656-5664.
- Galli G, Nuti S, Tavarini S, et al. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. *J Exp Med*. 2003;197:1051-1057.
- Spriggs MK, Armitage RJ, Strockbine L, et al. Recombinant human CD40 ligand stimulates B cell

This work was supported by the National Health and Medical Research Council (NHMRC) of Australia (Canberra, Australia). C.S.M. is a Peter Doherty Research Fellow, and S.G.T. is a Senior Research Fellow of the NHMRC.

Authorship

Contribution: D.T.A., C.S.M., and V.L.B. performed experiments and analyzed results; B.S.-N. and R.N. provided cord blood samples; M.W., D.A.F., and M.C.C. provided patient samples; D.A.F. and M.C.C. contributed to interpretation of the results and preparing the manuscript; and S.G.T. conceptualized and designed the research, performed experiments, analyzed results, and wrote the paper; all authors commented on the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Stuart G. Tangye, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst 2010, NSW, Australia; e-mail: s.tangye@garvan.org.au.

- proliferation and immunoglobulin E secretion. *J Exp Med*. 1992;176:1543-1550.
38. Hasbold J, Lyons AB, Kehry MR, Hodgkin PD. Cell division number regulates IgG1 and IgE switching of B cells after stimulation by CD40 ligand and IL-4. *Eur J Immunol*. 1998;28:1040-1051.
39. Johansson-Lindbom B, Borrebaeck CA. Germinal center B cells constitute a predominant physiological source of IL-4: implication for Th2 development in vivo. *J Immunol*. 2002;168:3165-3172.
40. Vercelli D, Jabara HH, Arai K, Yokota T, Geha RS. Endogenous interleukin 6 plays an obligatory role in interleukin 4-dependent human IgE synthesis. *Eur J Immunol*. 1989;19:1419-1424.
41. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. *Annu Rev Immunol*. 1998;16:293-322.
42. Leonard WJ. Cytokines and immunodeficiency diseases. *Nat Rev Immunol*. 2001;1:200-208.
43. Asao H, Okuyama C, Kumaki S, et al. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. *J Immunol*. 2001;167:1-5.
44. Konforte D, Paige CJ. Identification of cellular intermediates and molecular pathways induced by IL-21 in human B cells. *J Immunol*. 2006;177:8381-8392.
45. Brenne AT, Ro TB, Waage A, et al. Interleukin-21 is a growth and survival factor for human myeloma cells. *Blood*. 2002;99:3756-3762.
46. Habib T, Senadheera S, Weinberg K, Kaushansky K. The common gamma chain (gamma c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. *Biochemistry*. 2002;41:8725-8731.
47. Diehl SA, Schmidlin H, Nagasawa M, et al. STAT3-mediated up-regulation of BLIMP1 is coordinated with BCL6 down-regulation to control human plasma cell differentiation. *J Immunol*. 2008;180:4805-4815.
48. Defrance T, Aubry JP, Rousset F, et al. Human recombinant interleukin 4 induces Fc epsilon receptors (CD23) on normal human B lymphocytes. *J Exp Med*. 1987;165:1459-1467.
49. Pene J, Chretien I, Rousset F, et al. Modulation of IL-4-induced human IgE production in vitro by IFN-gamma and IL-5: the role of soluble CD23 (s-CD23). *J Cell Biochem*. 1989;39:253-264.
50. Ohga S, Nomura A, Ihara K, et al. Cytokine imbalance in hyper-IgE syndrome: reduced expression of transforming growth factor beta and interferon gamma genes in circulating activated T cells. *Br J Haematol*. 2003;121:324-331.
51. Del Prete G, Tiri A, Maggi E, et al. Defective in vitro production of gamma-interferon and tumor necrosis factor-alpha by circulating T cells from patients with the hyper-immunoglobulin E syndrome. *J Clin Invest*. 1989;84:1830-1835.
52. Rousset F, Robert J, Andary M, et al. Shifts in interleukin-4 and interferon-gamma production by T cells of patients with elevated serum IgE levels and the modulatory effects of these lymphokines on spontaneous IgE synthesis. *J Allergy Clin Immunol*. 1991;87:58-69.
53. Borges WG, Augustine NH, Hill HR. Defective interleukin-12/interferon-gamma pathway in patients with hyperimmunoglobulinemia E syndrome. *J Pediatr*. 2000;136:176-180.
54. Netea MG, Schneeberger PM, de Vries E, et al. Th1/Th2 cytokine imbalance in a family with hyper-IgE syndrome. *Neth J Med*. 2002;60:349-353.
55. Kishida T, Hiromura Y, Shin-Ya M, et al. IL-21 induces inhibitor of differentiation 2 and leads to complete abrogation of anaphylaxis in mice. *J Immunol*. 2007;179:8554-8561.
56. Avery DT, Bryant VL, Ma CS, de Waal Malefyt R, Tangye SG. IL-21-induced isotype switching to IgG and IgA by human naive B cells is differentially regulated by IL-4. *J Immunol*. 2008;181:1767-1779.
57. Fujita K, Jumper MD, Meek K, Lipsky PE. Evidence for a CD40 response element, distinct from the IL-4 response element, in the germline epsilon promoter. *Int Immunol*. 1995;7:1529-1533.
58. Fear DJ, McCloskey N, O'Connor B, Felsenfeld G, Gould HJ. Transcription of Ig germline genes in single human B cells and the role of cytokines in isotype determination. *J Immunol*. 2004;173:4529-4538.
59. Shapira SK, Vercelli D, Jabara HH, Fu SM, Geha RS. Molecular analysis of the induction of immunoglobulin E synthesis in human B cells by interleukin 4 and engagement of CD40 antigen. *J Exp Med*. 1992;175:289-292.
60. Jumper MD, Splawski JB, Lipsky PE, Meek K. Ligation of CD40 induces sterile transcripts of multiple Ig H chain isotypes in human B cells. *J Immunol*. 1994;152:438-445.
61. Milner JD, Brechley JM, Laurence A, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. *Nature*. 2008;452:773-776.
62. King CL, Gallin JI, Malech HL, Abramson SL, Nutman TB. Regulation of immunoglobulin production in hyperimmunoglobulin E recurrent-infection syndrome by interferon gamma. *Proc Natl Acad Sci U S A*. 1989;86:10085-10089.
63. Wood PM, Fieschi C, Picard C, et al. Inherited defects in the interferon-gamma receptor or interleukin-12 signalling pathways are not sufficient to cause allergic disease in children. *Eur J Pediatr*. 2005;164:741-747.
64. Stumhofer JS, Silver JS, Laurence A, et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. *Nat Immunol*. 2007;8:1363-1371.
65. Lecart S, Morel F, Noraz N, et al. IL-22, in contrast to IL-10, does not induce Ig production, due to absence of a functional IL-22 receptor on activated human B cells. *Int Immunol*. 2002;14:1351-1356.
66. Harris MB, Chang CC, Berton MT, et al. Transcriptional repression of Stat6-dependent interleukin-4-induced genes by BCL-6: specific regulation of epsilon transcription and immunoglobulin E switching. *Mol Cell Biol*. 1999;19:7264-7275.
67. Pernis AB. The role of IRF-4 in B and T cell activation and differentiation. *J Interferon Cytokine Res*. 2002;22:111-120.